Borghi Claudio, Prandin Maria Grazia, Dormi Ada, Ambrosioni Ettore
Department of Internal Medicine, University of Bologna, Bologna, Italy.
Blood Press Suppl. 2003 May;1:14-21. doi: 10.1080/08038020310000087.
The objective of this 8-week open-label study was to compare the tolerability of lercanidipine, a dihydropyridine calcium-channel antagonist (CA), with that of other CAs in the treatment of hypertension. Subjects already taking amlodipine, felodipine, nifedipine gastrointestinal therapeutic system (GITS), or nitrendipine and experiencing CA-specific adverse effects (AEs) were switched to lercanidipine for 4 weeks and then rechallenged with their initial treatment for 4 weeks. Results showed that at comparable levels of BP, lercanidipine was associated with a significantly lower incidence of ankle edema, flushing, rash, headache and dizziness compared with other CAs (p < 0.001). After 4 weeks of lercanidipine, mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) was 142.1/86.7 mmHg. After rechallenge with other CAs for 4 weeks, mean SBP/DBP was 141.1/86.7 mmHg. In this open-label study, lercanidipine compared with other CA seems to provide a significant improvement in tolerability with comparable antihypertensive effect.
这项为期8周的开放标签研究的目的是比较二氢吡啶类钙通道拮抗剂（CA）乐卡地平与其他钙通道拮抗剂在治疗高血压方面的耐受性。已服用氨氯地平、非洛地平、硝苯地平胃肠道治疗系统（GITS）或尼群地平并出现钙通道拮抗剂特异性不良反应（AE）的受试者改用乐卡地平治疗4周，然后再接受初始治疗4周。结果显示，在血压水平相当的情况下，与其他钙通道拮抗剂相比，乐卡地平引起的踝部水肿、潮红、皮疹、头痛和头晕的发生率显著更低（p<0.001）。服用乐卡地平4周后，平均收缩压（SBP）/舒张压（DBP）为142.1/86.7 mmHg。在用其他钙通道拮抗剂再次治疗4周后，平均SBP/DBP为141.1/86.7 mmHg。在这项开放标签研究中，与其他钙通道拮抗剂相比，乐卡地平在耐受性方面似乎有显著改善，且降压效果相当。
